We propose that our findings have clinical impact for patients with DLBCL that is positive for the IL‐6 receptor and also positive for phosphorylated STAT3, which acts downstream of IL‐6 signaling and has been known for a number of years to be a strong negative predictor of DLBCL patient survival. This evidence concerns the gene IL6 and diffuse large B-cell lymphoma.